TNF Pharmaceuticals (NASDAQ:TNFA) Posts Earnings Results

TNF Pharmaceuticals (NASDAQ:TNFA) announced its earnings results on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, Zacks reports.

TNF Pharmaceuticals Stock Performance

TNF Pharmaceuticals stock opened at $0.20 on Friday. The firm’s 50-day moving average is $0.28 and its 200-day moving average is $0.78. TNF Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $2.16. The company has a market cap of $2.00 million, a P/E ratio of -0.02 and a beta of 2.13.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.